Pilot Study of Ranibizumab (Lucentis) for Neurofibromas Associated With Neurofibromatosis 1
Phase of Trial: Phase 0
Latest Information Update: 11 Jul 2016
At a glance
- Drugs Ranibizumab (Primary)
- Indications Neurofibroma
- Focus Biomarker; Pharmacodynamics
- 31 Aug 2018 Biomarkers information updated
- 06 Jul 2016 Status changed from active, no longer recruiting to completed.
- 13 Aug 2015 The recruitment status of this study is unknown because the information has not been verified recently (Verified on March 2013 ). So kept previous status as active not recruiting as per ClinicalTrials.gov record.